D-0137-2017 Class III Terminated
FDA drug recall D-0137-2017 was initiated by Amerisource Health Services on Oct 27, 2016 and is designated Class III. Reason for recall: Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples. The recall status is terminated (terminated Jun 29, 2017). Affected quantity: a) 15,409 bottles b) 5,128 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 23, 2016
- Initiation Date
- Oct 27, 2016
- Termination Date
- Jun 29, 2017
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- a) 15,409 bottles b) 5,128 bottles
Product description
Bupropion Hydrochloride Extended-Release Tablets, USP (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05), b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India For BluePoint Laboratories
Reason for recall
Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.
Distribution pattern
Nationwide and Puerto Rico
Code information
Lot #: a) M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018; M604444, Exp 4/30/2018; M606515, Exp 4/30/2018.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0137-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026